摘要
为解决高值药物准入对医保可持续性的影响,各国积极探索管理准入在提高高值药物可及性、降低医保基金风险等方面的作用,并取得了一定成效。本研究系统梳理了澳大利亚高值药物管理准入的相关政策,包括药物遴选、协议制定、实施管理、数据收集以及药物再审查等,比较分析澳大利亚高值药物管理准入和我国谈判准入政策,为我国进一步完善高值药物医保准入政策提供启示与借鉴。
In order to solve the impact of the entry of high-value drugs on the sustainability of medical insurance,some countries have actively explored the role of managed entry in improving the availability of high-value drugs and reducing the risk of medical insurance funds,and achieved certain success.This research systematically sorted out the relevant policies of Australia's managed entry scheme for high-value drugs,including drug selection,agreement formulation,implementation management,data collection,and post-market reviews,and compared and analyzed Australia's managed entry scheme for high-value drugs and our country's negotiation access policy,thus to provide enlightenment and reference for our country to further improve the medical insurance access policy of highvalue drugs.
作者
汤静琪
张晓
TANG Jing-qi;ZHANG Xiao(School of Public Health,Southeast University,Nanjing 210009,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2021年第12期1073-1078,共6页
Chinese Journal of New Drugs
基金
国家自然科学基金资助项目(71373042)。
关键词
管理准入协议
医保准入
高值药物
managed entry arrangement
medical insurance access
high-value drugs
